Background
==========

In normal, euthyroid individuals, 20% of the circulating active thyroid hormone triiodothyronine (T~3~) comes directly from the thyroid gland and 80% is produced in non-thyroidal tissues by the activation of the inactive prohormone thyroxine (tetraiodothyronine, T~4~) [@bib1] [@bib2]. Low T~3~ concentrations are found during starvation and in various acute and chronic illnesses [@bib3] [@bib4] [@bib5]. This condition is variously referred to as the euthyroid sick syndrome (ESS), non-thyroidal illness (NTI) syndrome or the low T~3~ syndrome (LT~3~S) [@bib4] [@bib5] [@bib6]. In critically ill patients, T~4~ concentrations may also be low, and the degree of disturbance in the circulating thyroid hormone concentrations is related to the severity of the NTI, with a decrease in the T~3~ concentration only being more benign [@bib5] [@bib6]. LT~3~S as found in ESS is caused by a decrease in enzymatic deiodination at the 5′ position of the outer, phenol ring of the iodothyronines [@bib2] [@bib7]. In more severe NTIs, there is a further reduction in T~3~ concentrations due to increased deiodination at the 5 position of the inner, tyrosyl ring reducing it to the inactive diiodothyronine (T~2~) and producing inactive reverse T~3~ (rT~3~) from T~4~, thereby yet further reducing T~3~ generation because of decreased substrate availability [@bib2] [@bib7] [@bib8]. Evidence of a disturbance in the thyroid-stimulating hormone (TSH) feedback loop has also been found [@bib4] [@bib5] [@bib6] [@bib8]. LT~3~S is also found in response to some drugs, including propylthiouracil (PTU) [@bib9], beta-blockers [@bib10] and amiodarone [@bib11] [@bib12].

The enzymes responsible for these alterations are the deiodinases (D) D1, D2 and D3 [@bib2] [@bib7]. D2 is an activating enzyme that converts T~4~ to T~3~ (and rT~3~ to T~2~) and is found in the endothelial reticulum of skeletal muscle, CNS, pituitary, thyroid, heart muscle and brown adipose tissue. D3 is a deactivating enzyme that converts T~4~ to rT~3~ and T~3~ to T~2~ and is found in the CNS and other tissues. D1 has both activating and deactivating activities and is found in the plasma membranes of liver, kidney, thyroid and pituitary tissue. Together, theses three enzymes play a vital role in the maintenance of tissue and circulating thyroid hormone levels [@bib2] [@bib7].

The 5′-deiodinase activity of D1 is inhibited by fasting, PTU and amiodarone [@bib3] [@bib9] [@bib11] [@bib12]. Melmed *et al*. [@bib11] have shown that the decreased generation of T~3~ caused by chronic amiodarone administration in euthyroid patients causes a compensatory increase in TSH and T~4~ concentrations. It is accompanied by a more modest increase in rT~3~ concentrations, which is partially explainable by the mass action effect of the marked increase in TSH-stimulated T~4~ secretion by the thyroid gland, but in addition represents some increase in D1 activity through its increased half-life caused by the increased secretion of T~3~ by the intact thyroid gland in response to the increased TSH concentration [@bib2] [@bib7].

Treatment of LT~3~S secondary to NTIs with levothyroxine ([l]{.smallcaps}-T~4~) has generally been found to be unsuccessful [@bib4] [@bib5] [@bib6].

Herein, we report on two patients with clinical evidence of hypothyroidism and LT~3~S without any of the usual causes.

Case presentations
==================

Case 1
------

A 63-year-old man, diagnosed at the age of 31 years with primary hypothyroidism due to Hashimoto\'s autoimmune thyroiditis when he received the first of two mitral valve replacements, was referred for continued severe cold intolerance, low physical energy and marked mental lethargy in spite of free T~4~ concentrations being near the upper limit of the reference range on [l]{.smallcaps}-T~4~ replacement. His weight was 98 kg. There was no goitre. He was on warfarin and on candesartan, verapamil, furosemide and digoxin therapy for hypertension and congestive heart failure and on allopurinol therapy for gout. There was no history of herpes or any other chronic viral infection.

Case 2
------

A 60-year-old woman was referred for the evaluation of fatigue, cold intolerance, muscle cramps, depression and obesity of long duration. Her weight was 99 kg. There was no goitre. She was on candesartan and nifedipine therapy for hypertension. There was no history of herpes or any other chronic viral infection.

Investigation
=============

Case 1
------

Thyroid tests revealed elevated thyroid peroxidase antibody (TPOA) levels, free T~4~ levels near the upper limit of the reference range, markedly elevated TSH levels and low free T~3~ levels. The T~4~:T~3~ ratio was high, rT~3~ concentrations were in the normal reference range, and the T~4~:rT~3~ ratio was more than double mid-normal. Plasma iodine concentration was within the reference range ([Table 1](#tbl1){ref-type="table"}).

###### 

Clinical features and thyroid hormone levels in the two patients with atypical low T~3~ syndrome

  **Patient, age, gender and treatment**                      **TSH** (mU/l)    **T~4~** (pmol/l)   **T~3~** (pmol/l)   **T~4~/T~3~** (Ratio)   **rT~3~** (nmol/l)   **T~4~/rT~3~** (Ratio)
  ----------------------------------------------------------- ----------------- ------------------- ------------------- ----------------------- -------------------- ------------------------
  1\. 63 years, male and TTPH on 75 μg [l]{.smallcaps}-T~4~   **38.8**          19.2                **3.0**             **6.4**                                      
      Repeat on 75 μg [l]{.smallcaps}-T~4~                    **36.5**          17.5                **3.1**             **5.6**                 0.19                 **92.1**
      On 100 μg [l]{.smallcaps}-T~4~                          **20.6**          **23.6**            **3.4**             **6.9**                                      
      Repeat on 100 μg [l]{.smallcaps}-T~4~                   **14.7**          **22.5**            **3.1**             **7.3**                 0.23                 **97.8**
  2\. 60 years, female and before treatment                   1.50              19.8                **3.4**             **5.8**                 --                   --
      On 150 μg [l]{.smallcaps}-T~4~                          **\<** **0.06**   **21.6**            **3.3**             **6.5**                 0.54                 40.0
  **Analytical units**                                                                                                                                               
    Normal reference range                                    0.38--5.5         10.5--20            3.5--6.5                                    0.14--0.54           
    Mid-normal values                                         1.5               15.3                5.0                 3.1                     0.34                 45

TTPH, thyroxine-treated primary hypothyroidism. Analyte levels are given in bold if outside the reference range. Patient 1: plasma iodine: 0.29 (*n*: 0.24--0.63 μmol/l).

Case 2
------

Thyroid tests revealed normal TPOA levels and TSH and T~4~ levels within their reference ranges, but low T~3~ concentrations and an elevated T~4~:T~3~ ratio ([Table 1](#tbl1){ref-type="table"}).

Thyroid hormone measurements were carried out by LifeLabs Laboratory Services, 3680 Gilmore Way, Burnaby, BC, V5G 4V8, Canada, using a competitive immunoassay with direct chemiluminescent technology for TSH, T~4~ and T~3~ and electrochemiluminescent immunoassay for TPOA. The rT~3~ concentration was measured by Associated Regional and University Pathologist (ARUP), Inc., 500 Chipeta Way, Salt Lake City, UT, 84108, USA, using a competitive RIA. Plasma iodine measurement was carried out by the London Laboratory Services Group, PO Box 5010, London, ON, N6A 5W9, Canada, using high-resolution inductively coupled plasma mass spectroscopy.

Treatment
=========

Case 1
------

Increasing [l]{.smallcaps}-T~4~ dose to 100 μg had no effect on the symptoms in spite of T~4~ concentrations rising to supraphysiological levels, TSH concentrations falling to half their previous levels, a minimal to no increase in T~3~ concentrations, and a further rise in the T~4~:T~3~ ratio. The rT~3~ concentration rose minimally and continued to fall within the reference range, and the T~4~:rT~3~ ratio remained more than double normal ([Table 1](#tbl1){ref-type="table"}). Because of the patient\'s heart failure, it was thought inadvisable to further increase the dose of [l]{.smallcaps}-T~4~.

Case 2
------

Treatment with 150 μg [l]{.smallcaps}-T~4~ had no clinical effect, increased T~4~ concentrations and T~4~:T~3~ ratio, and suppressed TSH concentrations, but had no effect on T~3~ concentrations. The rT~3~ concentration remained within the reference range, and the T~4~:rT~3~ ratio was near the mid-normal level ([Table 1](#tbl1){ref-type="table"}).

Discussion
==========

Herein, we report on two patients with atypical LT~3~S in that they reported none of the usual causes such as NTIs, including chronic viral infections, starvation and mediations known to cause impaired T~3~ generation or its increased destruction. Their rT~3~ concentrations were not elevated, as is the case in more severe NTIs or if on amiodarone therapy [@bib2] [@bib7] [@bib8] [@bib11] [@bib12]. In both patients, the negative TSH feedback mechanism was intact in that their TSH levels fell in response to increasing doses of [l]{.smallcaps}-T~4~, albeit that in patient 1 the levels remained markedly elevated. Both presented with clinical symptoms of hypothyroidism, but neither responded clinically to elevating the T~4~ concentrations to supraphysiological levels, and nor was there a consistent increase in T~3~ concentrations.

The findings in patient 1 are reminiscent of those found in euthyroid patients on amiodarone therapy as reported by Melmed *et al*. [@bib11] and Rosene *et al*. [@bib12], except that TSH levels remained markedly elevated even at supraphysiological concentrations of T~4~ and that the T~4~:rT~3~ ratio was elevated ([Table 1](#tbl1){ref-type="table"}). It is consistent with an absent response of the thyroid gland to elevated TSH levels because of the patient\'s primary hypothyroidism. In fact, he might not have come to attention if he had not also had primary hypothyroidism in that the elevated TSH levels would presumably have resulted in increased secretion of thyroid hormones and suppression of TSH secretion. Inhibition of the deiodinases due to elevated serum iodine levels was ruled out ([Table 1](#tbl1){ref-type="table"}). The findings are most consistent with a marked decrease in D1 activity including normal rT~3~ concentrations, which might be considered inappropriately low given the elevated T~4~ concentrations, resulting in a high T~4~:rT~3~ ratio ([Table 1](#tbl1){ref-type="table"}).

Patient 2 had previously not been diagnosed with hypothyroidism and had a negative TPOA concentration. Unlike in patient 1, the rT~3~ concentration at the upper limit of the reference range was appropriate for the elevated concentration of its substrate T~4~, as indicated by the mid-normal T~4~:rT~3~ ratio ([Table 1](#tbl1){ref-type="table"}). It is evidence that the activity of D1 at the 5 position of the inner ring was not impaired. As the enzymatic activities of D1 at the 5 and 5′ positions have been shown to proceed in an equimolar fashion [@bib2], it makes decreased D1 activity an unlikely cause of the low circulating T~3~ levels, suggesting impaired D2 activity as a more likely alternative. She also differed from patient 1 in not having an elevated TSH concentration, albeit that the 1.5 concentration was higher than expected for a T~4~ concentration at the upper limit of the reference range ([Table 1](#tbl1){ref-type="table"}). It has long been known that TSH secretion is controlled by a negative feedback mechanism responsive to circulating T~4~ concentrations [@bib1]. It is the concentration of T~3~ at the nuclear T~3~ receptors of the thyrotrophs produced by the resident D1 and D2 enzymes as well as the T~3~ from the circulation that ultimately controls TSH secretion [@bib2]. Christoffolete *et al*. [@bib13] have demonstrated a unique behaviour of D2 in thyrotrophs in being able to overcome ubiquitination, thereby sustaining net increased T~3~ production at increasing T~4~ concentrations. One might speculate that in patient 2 the postulated decreased D2 activity might be sufficiently ameliorated by its atypical expression in the thyrotrophs to result in no or only minimally elevated TSH levels. An additional possible mechanism may be that reduced T~3~ levels in the hypothalamus caused by decreased D2 activity in the third ventricle tanycytes have reset the TSH response of the thyrotrophs [@bib14]. The lack of a markedly elevated TSH concentration in patient 2 may be akin to what has been observed in patients on amiodarone therapy in whom after an initial elevation in TSH concentrations in response to impaired deiodinase activity [@bib11] [@bib12], there is a gradual return to normal or nearly normal levels.

The theoretically possible alternative cause for the low circulating T~3~ levels of a deficiency in T~3~ production by the thyroid gland is not applicable in patient 1 who had Hashimoto\'s primary hypothyroidism, while in patient 2 the 32% observed reduction from mid-normal levels exceeds the 20% of the total T~3~ contributed by the thyroid [@bib1] [@bib2], and nor would it explain the lack of an increase in T~3~ concentrations as the T~4~ concentration rose in response to increasing the dose of [l]{.smallcaps}-T~4~. Furthermore, no such case has been reported. It was not ruled out in either patient that further increases in their T~4~ concentrations by increased doses of [l]{.smallcaps}-T~4~ might have resulted in an increase in T~3~ concentrations.

The fact that both patients responded with a decrease in TSH concentrations in response to an increase in circulating T~4~ concentrations indicated an intact negative TSH feedback axis, supporting evidence for the lack of NTIs as a potential cause for the abnormalities found [@bib4] [@bib6] [@bib8]. This, together with the lack of clinical evidence that their LT~3~S was secondary to fasting, NTIs or drugs, suggests that the alterations in circulating thyroid hormone levels were not secondary, but might represent primary abnormalities in deiodinase activity. In support of this speculation, Peeters *et al*. [@bib15] have demonstrated polymorphism of deiodinases associated with circulating iodothyronine concentrations and their ratios, while Panicker *et al*. [@bib16] using a similar approach of nucleotide measurement of genes involved in thyroid hormone metabolism found that 26% of patients with primary hypothyroidism on replacement therapy had polymorphism in the *DIO2* gene resulting in a decreased T~4~:T~3~ ratio and clinical manifestations. Considering this frequency in genetic polymorphism, it is not unexpected that patients might be encountered with primary D2 and D1 enzyme abnormalities causing LT~3~S.
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